These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34104398)

  • 1. Low complication rates of testosterone and estradiol implants for androgen and estrogen replacement therapy in over 1 million procedures.
    Donovitz GS
    Ther Adv Endocrinol Metab; 2021; 12():20420188211015238. PubMed ID: 34104398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous testosterone pellet implant (Testopel) therapy for men with testosterone deficiency syndrome: a single-site retrospective safety analysis.
    Cavender RK; Fairall M
    J Sex Med; 2009 Nov; 6(11):3177-92. PubMed ID: 19796052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of testosterone implants for androgen replacement therapy.
    Handelsman DJ; Mackey MA; Howe C; Turner L; Conway AJ
    Clin Endocrinol (Oxf); 1997 Sep; 47(3):311-6. PubMed ID: 9373452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moderate dosage estrogen-androgen therapy improves continuation rates in postmenopausal women: impact of the WHI reports.
    Gambrell RD; Natrajan PK
    Climacteric; 2006 Jun; 9(3):224-33. PubMed ID: 16766436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants.
    Kelleher S; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2001 Oct; 55(4):531-6. PubMed ID: 11678837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K; Neuenschwander PF; Kurdowska AK
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety outcomes of a compounded testosterone pellet versus a branded testosterone pellet in men with testosterone deficiency: a single-center, open-label, randomized trial.
    Kresch E; Lima TFN; Molina M; Deebel NA; Reddy R; Patel M; Loloi J; Carto C; Nackeeran S; Gonzalez DC; Ory J; Ramasamy R
    Sex Med; 2023 Apr; 11(2):qfad007. PubMed ID: 36936900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone release rate and duration of action of testosterone pellet implants.
    Kelleher S; Howe C; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):420-8. PubMed ID: 15049955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study.
    Glaser RL; Dimitrakakis C
    Maturitas; 2013 Dec; 76(4):342-9. PubMed ID: 24028858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for Treatment of Symptoms Associated With Androgen Deficiency.
    McMahon CG; Shusterman N; Cohen B
    J Sex Med; 2017 Jul; 14(7):883-890. PubMed ID: 28673432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
    Traish AM
    Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extrusion of testosterone pellets: a randomized controlled clinical study.
    Kelleher S; Turner L; Howe C; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 1999 Oct; 51(4):469-71. PubMed ID: 10583314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets.
    Pastuszak AW; Mittakanti H; Liu JS; Gomez L; Lipshultz LI; Khera M
    J Androl; 2012; 33(5):927-37. PubMed ID: 22403285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which androgen replacement therapy for women?
    Buckler HM; Robertson WR; Wu FC
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3920-4. PubMed ID: 9814469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast Cancer Incidence Reduction in Women Treated with Subcutaneous Testosterone: Testosterone Therapy and Breast Cancer Incidence Study.
    Donovitz G; Cotten M
    Eur J Breast Health; 2021 Apr; 17(2):150-156. PubMed ID: 33870115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised controlled clinical trial of antibiotic impregnation of testosterone pellet implants to reduce extrusion rate.
    Kelleher S; Conway AJ; Handelsman DJ
    Eur J Endocrinol; 2002 Apr; 146(4):513-8. PubMed ID: 11916619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone implants in women: pharmacological dosing for a physiologic effect.
    Glaser R; Kalantaridou S; Dimitrakakis C
    Maturitas; 2013 Feb; 74(2):179-84. PubMed ID: 23265303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study.
    Gittelman M; Jaffe JS; Kaminetsky JC
    J Sex Med; 2019 Nov; 16(11):1741-1748. PubMed ID: 31551193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coadministration of anastrozole sustains therapeutic testosterone levels in hypogonadal men undergoing testosterone pellet insertion.
    Mechlin CW; Frankel J; McCullough A
    J Sex Med; 2014 Jan; 11(1):254-61. PubMed ID: 24119010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadism.
    Zacharin MR; Pua J; Kanumakala S
    Clin Endocrinol (Oxf); 2003 Jun; 58(6):691-5. PubMed ID: 12780744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.